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HbA1cA B S T R A C T
Aims: To compare the quality of diabetes care among type 2 diabetes patients with and
without mental disorders during six-year follow-up in North Karelia, Finland.
Methods: All type 2 diabetes patients (n = 10190) were analysed using the electronic health
records data from 2011–12 to 2015–16. The diabetes care was evaluated using the measure-
ment activity and the achievement of the treatment targets for HbA1c and LDL.
Results: Monitoring of HbA1c and LDL levels improved among all patient groups, except the
dementia patients. The proportion of those achieving the HbA1c target declined and those
achieving the LDL target improved in all patient groups. Differences in the changes of
achievement of the target HbA1c level among patients with dementia and depression were
observed when compared with those having only type 2 diabetes.
Conclusions: This study highlights the challenge of glucose level management as the age
and comorbidities of the patients related to the care and achievements of the treatment
targets. Mental disorders that are likely to affect patients’ adherence to medication and
other treatments should be taken into account and more support for self-care should be
provided to such patients. Improvement in the achievement of LDL target address the pro-
gress in the prevention of macrovascular complications.
 2020 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Almost 463 million adults are living with diabetes around the
world. It is one of themost common and costly chronic health
problems worldwide [1]. Comorbidities in type 2 diabetes
patients are common and often worsen the quality of care.Type 2 diabetes patients with mental disorders aremore likely
to have worse quality of diabetes care and thus poorer treat-
ment outcomes [2,3] and more diabetic complications than
patients without them [4]. It has been shown that people with
diabetes and mental disorder have inadequate adherence to
drugs, much less self-care conformity, and more functional
2 d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 6 ( 2 0 2 0 ) 1 0 8 3 1 2impairment. This patient behaviour enhances the danger of
diabetes-related complications, raises the possibility of very
early death and increases healthcare expenses [5,6].
A commonmental health illness that has been found to be
associated with type 2 diabetes is depression. An increased
prevalence of depression among type 2 diabetes patients is
well documented. A meta-analysis by Anderson and his col-
leagues found that the presence of diabetes doubles the
chances of having depression [7]. Diabetes along with
depression caused poor clinical outcomes [8] and more
diabetes-related complications [9]. Depressive patients had
low motivation for self-care, which leads to poor physical
and psychological conditions. They were also found to use
more health care services compared with those without men-
tal disorder [10,11]. The chances of cardiovascular mortality
also increased with the combined presence of depression
and type 2 diabetes [12,13]. The effect of the coexistence of
depression and diabetes was much worse on all-cause and
coronary heart disease mortality than when each illness
occurred individually [14].
Type 2 diabetes individuals are at risk of suffering from
dementia as well. A meta-analysis of prospective observa-
tional studies found that type 2 diabetes patients had a 73%
greater risk of all types of dementia [15]. Furthermore, a
population-based cohort study from Ontario, Canada
observed that there was a 16% increased risk of dementia
among newly-diagnosed elderly type 2 diabetes patients
[16]. A significant predictor of cognitive dysfunction was the
presence of type 2 diabetes. The association of type 2 diabetes
and cognitive impairment has been researched extensively
[17–20]. The main concern of the existence of cognitive
impairment in a type 2 diabetes patient was that it affects
the self-management and quality of life of the patient [21].
Planning, attention, memory, problem-solving and learning
skills were found to be decreased in type 2 diabetes patients
with cognitive impairment [22].
Quality of diabetes care among patients with mental disor-
ders has previously been studied internationally. However,
there are differences in study populations, designs and set-
tings, which makes it difficult to make conclusions on the
effect of mental disorder on the quality of diabetes care
[4,23–25]. Some studies have shown poor quality of diabetes
care among patients with a mental disorder [11,24,26], while
others did not find any disparities [25,27]. A study observing
the quality of diabetes care through retrospective analysis of
administrative data among patients with and without mental
disorder found that type 2 diabetes patients who have a co-
existence of mental disorder had more health care visits
and had fewer HbA1c and cholesterol measurements. Less
than 6% of patients received the recommended care provided
by the American Diabetes Association [4].
In Finland, the quality of diabetes care at the national level
has been evaluated in few studies [28–30], and information on
the quality of diabetes care among type 2 diabetes patients
with mental disorder is missing. The aim of this study is to
provide long-term information on the quality of diabetes care
among type 2 diabetes patients with and without mental dis-
orders, and to compare the quality of care between these
patient groups during a six-year follow-up. In order toevaluate the quality of diabetes care, we have used two pro-
cess of care indicators (HbA1c measurement rate and LDL
measurement rate) and two outcome of care indicators
(achievement of the target level of HbA1c <7% or 53mmol/mol
and LDL <2.5 mmol/l).
2. Methods
2.1. Study design and setting
This is a retrospective cohort study using data from the regio-
nal electronic health records (EHR) of North Karelia, Finland,
from 2011 to 2016. In Finland, municipalities are responsible
for organising and financing health care and most of the ser-
vices are public providing inhabitants an equal access to ser-
vices [31]. In North Karelia, the joint municipal authority
organizes both primary and secondary level services for 13
municipalities. A common electronic patient database system
called Mediatri is used in health services. The database
includes details on patients’ age, gender, place of residence,
other permanent diagnoses and key laboratory markers, and
has been in use since the beginning of 2011 both in primary
and specialised care. The ethics approval for the study was
received from the Ethics Committee of the Northern Savonia
Hospital District on 13 November 2012.
We included data on patients’ age, gender, HbA1c and LDL
levels, and their permanent diagnosis, such as type 2 diabetes
(ICD-10 code E11), dementia (ICD-10 code F00-F03 & G30),
depression (ICD-10 code F32-F33) and other mental disorders,
such as schizophrenia, mood and neurotic disorders (ICD-10
code F20-F48 except F32-F33) from 2011 to 2016.
2.2. Participants
All patients who had visited a health care centre with the
diagnosis of type 2 diabetes were identified from the Mediatri
database and were checked by physicians for confirmation of
diagnosis. After that, patients who had dementia, depression
or other mental disorder along with type 2 diabetes were
identified by registered permanent diagnoses in the EHR. At
the end of 2012, a total of 10,197 individuals with type 2 dia-
betes were alive living in the North Karelia region. We
included only those aged 20 or older and ended up with a total
of 10,190 type 2 diabetes patients at baseline. Among them,
618 had dementia, 771 had depression, 715 had another men-
tal disorder and 8171 had only type 2 diabetes.
During the follow-up, a total of 1761 type 2 diabetes
patients died. Of them, 370 had dementia, 130 depression,
118 other mental disorder and 1187 only type 2 diabetes.
Therefore, overall a total of 8429 patients were available for
the follow-up (age  20) at the end of 2016. However, there
was some overlap among the mental disorder patient groups.
Some patients had both dementia and other mental disorder
(n = 28 in 2011–12; n = 13 in 2015–16) and others had both
dementia and depression (n = 57 in 2011–12; n = 28 in
2015–16).
For sensitivity analyses, we also identified patients who
had been diagnosed with dementia, depression or other
mental disorder during the follow-up. There were 351 new
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order cases diagnosed.
2.3. Variables
We assessed four measures of quality of care based on the
internationally accepted quality of care measurement indica-
tors [32]. Current Finnish care guidelines suggest that the
HbA1c level of type 2 diabetes patients should be monitored
at least once or twice in a year, and the LDL level should be
monitored at least once in a year or every three years depend-
ing on the previously achieved control [33]. Therefore, we
used HbA1c and LDL testing as process of care indicators dur-
ing the periods of 2011–12 and 2015–16.
According to Finnish Current care guidelines, the treat-
ment target of HbA1c is <7% or 53 mmol/mol and LDL is
<2.5 mmol/l. Therefore, the achievement of the target level
of HbA1c (<7% or 53 mmol/mol) and LDL (<2.5 mmol/l) among
those whose HbA1c or LDL level was measured both in 2011–
12 and 2015–16 were considered as indicators for the outcome
of care. Patients who had HbA1c measurements at least three
months after (n = 6070) and LDL measurement one month
after the diagnosis of type 2 diabetes (n = 5664) were taken
into consideration to ensure sufficient time for the treatment
to take effect. We categorised HbA1c levels as target met
(HbA1c <7% or <53 mmol/mol) and LDL as target met (LDL
<2.5 mmol/l) for the descriptive statistics and generalised
estimating equation modelling.
Variables for transition plot were categorised as (HbA1c
level 20–53 mmol/mol = very good, 53–64 mmol/mol = moder
ate, 64–75 mmol/mol = poor and 75–155 mmol/mol = very
poor control) and (LDL level 0–1.8 mmol/l = very good, 1.8–2.
5 mmol/l = moderate and 2.5–11 mmol/l = poor control).
2.4. Biochemical methods
HbA1c and LDL samples were analysed in the Eastern Finland
Laboratory Centre Joint Authority Enterprise (ISLAB), which is
an accredited laboratory and participates in external quality
surveys. HbA1c samples were analysed by the turbidimetric
inhibition immunoanalysis method (TINIA), and LDL samples
were analysed by the photometric direct enzymatic method.
All the values were standardised to International Federation
of Clinical Chemistry (IFCC) units’ levels.
2.5. Statistical method
We used IBM SPSS Statistics for Windows v. 25 for statistical
analysis. Counts, percentages and mean values were used to
describe the basic characteristics of the patient. Percentages
were reported with 95% CI andmeans for the continuous vari-
ables were presented with SD. To assess the differences in the
measurement rate and management of HbA1c and LDL
among patients with depression, dementia and other mental
disorders compared with those who had only type 2 diabetes
at the baseline (2011–12), we performed logistic and linear
regression models with generalised estimating equations
(GEE), as this can account for repeated measurements. Loga-
rithmic transformations were performed only for the skewed
independent variable HbA1c before the analysis and LDLlevels were normally distributed. Together with unadjusted
results, age- and gender-adjusted results are also reported.
P-values of less than 0.05 were regarded as statistically signif-
icant. Transition plots were used to illustrate the fluctuation
of patients HbA1c and LDL levels during the follow-up.3. Results
Table 1 presents the characteristics of the patients at baseline
and follow-up. There were more female patients with demen-
tia, depression and other mental disorder thanmales, and the
mean age of the patients was highest among patients with
dementia (Table 1).
The measurement rate of HbA1c improved during the
follow-up among all patient groups (from 78–82% to 83–89%)
and LDL monitoring also improved among all disease groups
(from 74–75% to 83–86%) except the dementia patients (from
53% to 51%) (Table 1). However, when mental disorder patient
groups were compared with only type 2 diabetes patients, a
significant difference in the changes of the HbA1c measure-
ment rate during the follow-up was observed only among
the dementia patient group. A similar trend was observed
for the LDL measurement rate (Supplement Table 1).
The highest achievement of the HbA1c target was
observed among patients with only type 2 diabetes (72% vs
67% in 2011–12 and 2015–16 respectively) and the achieve-
ment of the LDL target was the poorest among patients with
depression (50% vs 55% in 2011–12 and 2015–16 respectively)
(Table 1).
When we followed the patients whose HbA1c or LDL was
measured both at baseline and follow-up, we found variations
in outcomes of care indicators. The proportion of those
achieving the HbA1c target declined in all groups. When com-
paring the other patient groups with those having only type 2
diabetes using the age- and gender-adjusted logistic regres-
sion model with GEE, a significant difference in changes in
the achievement of HbA1c target from baseline to follow-up
was observed among dementia and depression patient groups
(Table 2).
An improvement in the achievement of the LDL target was
observed among all disease groups. Moreover, a significant
difference in changes in the achievement of LDL target from
baseline to follow-up was observed only among other mental
disorder group compared with only type 2 diabetes patients
(Other mental disorder: 53% vs 62%; Only type 2 diabetes:
55% vs 62% in 2011–12 and 2015–16 respectively; P = 0.037)
(Table 2).
Transition plots were drawn to observe the transition of
patients between different HbA1c- and LDL-level categories
during the follow-up. We found a considerable number of
patients moving from very good HbA1c control to moderate
control, and the patterns were similar for all groups (Fig. 1).
An opposite trend was observed in LDL control, where more
patients were moving towards moderate control from poor
control and the patterns were similar for all groups (Fig. 2).
In addition, type 2 diabetes patients who developed men-
tal disorders during the follow-up were analysed separately
to observe whether the achievement of treatment target
was affected by onset of mental disorders. We found that
Table 1 – Basic characteristics of patients at baseline and follow-up by disorder category.
Only type 2 diabetes Dementia Depression Other mental disorder
Baseline (2011–12)
Number of patients, n (%) 8171 (80) 618 (6) 771 (7) 715 (7)
Proportion of females, % 45 62 59 53
Age in yearsb, mean (SD) 68 (11.2) 82 (6.57) 63 (13.1) 62 (12.5)
HbA1c measured, % (95% CI) 78 (77–79) 79 (75–82) 78 (75–81) 82 (79–85)
LDL measured, % (95% CI) 75 (74–76) 53 (49–57) 75 (72–78) 74 (71–77)
HbA1c %, mean (SD)* 6.63 (1.18) 6.99 (1.30) 6.71 (1.39) 6.65 (1.36)
LDL mmol/l, mean (SD) ** 2.48 (0.83) 2.47 (0.86) 2.59 (0.88) 2.49 (0.86)
HbA1c <7% or 53 mmol/mol, % (95% CI) * 72 (71–74) 60 (55–64) 70 (67–74) 71 (68–75)
LDL <2.5 mmol/l, % (95% CI) ** 55 (54–56) 55 (50–61) 50 (46–54) 54 (50–58)
Follow-up (2015–16)
Number of patients, n (%) 6984 (83) 248 (3) 641 (8) 597 (7)
Proportion of females, % 45 66 61 53
Age in yearsb, mean (SD) 67 (10.9) 80 (6.78) 61 (12.5) 60 (11.9)
HbA1c measured, % (95% CI) 89 (88–89) 83 (78–88) 89 (86–91) 89 (87–92)
LDL measured, % (95% CI) 86 (85–87) 51 (45–58) 83 (79–85) 86 (83–89)
HbA1c %, mean (SD) + 6.84 (1.22) 7.06 (1.31) 6.88 (1.32) 6.80 (1.34)
LDL mmol/l, mean (SD) ++ 2.39 (0.86) 2.18 (0.89) 2.52 (1.01) 2.44 (0.88)
HbA1c <7% or 53 mmol/mol, % (95% CI) + 67 (66–69) 54 (47–61) 63 (59–67) 67 (63–71)
LDL <2.5 mmol/l, % (95% CI) ++ 61 (59–62) 69 (60–77) 55 (51–59) 61 (56–65)
Proportion of patient were calculated from total number of patients at baseline (n = 10190) and follow-up (n = 8429) respectively. However, there
are overlapping among patient groups.
b Age at the end of 2012.
*Patients whose HbA1c was measured at baseline (n = 7988) and **Patients whose LDL was measured at baseline (n = 7485).
+Patients whose HbA1c measured at follow-up (n = 7470) and ++Patients whose LDL measured at follow-up (n = 7128).
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were diagnosed with mental disorder at baseline. The
achievement of the HbA1c target declined among all disease
groups and the achievement of the LDL target improved
(Supplement Table 2).
4. Discussion
This study provided long-term information on the quality of
diabetes care among type 2 diabetes patients with and with-
out mental disorders and compared the quality of care
between these patient groups. We found that the monitoring
of HbA1c and LDL levels improved among all patient groups,
except the dementia patients. During the follow-up, the pro-
portion of those achieving the HbA1c target declined and
those achieving the LDL target improved in all patient groups.
The results from the previous studies evaluating the pro-
cess indicators of diabetes care among patients with and
without mental disorder have shown inconsistent results.
Frayne and his colleagues found that the process of care dif-
fers among patients with only type 2 diabetes compared with
those with a mental disorder. The odds of having no HbA1c or
LDL measurement was respectively 1.24 (1.22–1.27) and 1.25
(1.23–1.28) higher among patients with mental disorder com-
pared with those with no mental disorder [24]. Instead, nei-
ther the studies of Krein et al. nor Whyte et al. found any
difference in glucose monitoring among patients with only
type 2 diabetes compared with the patients with a mental dis-
order [25,27]. We observed differences in process of care indi-
cators among dementia patients comparedwith patients with
only type 2 diabetes. The results by Cooper et al., describingthe processes of care among dementia patients, are also in
line with our results. They found that dementia patients are
less likely to have primary care visits and annual weight
and blood pressure monitoring compared with patients with-
out dementia [34].
It is also observed that patients with dementia find it diffi-
cult and confusing to navigate health care services and often
end up using emergency services [35]. This could be one pos-
sible reason for the observed differences in process of care
indicators. Also, dementia patients are older and are more
likely to be served by homecare and treated on wards; thus,
all follow-up measurements might not have been recorded
to the patient records. Also, in reality, the need for active
monitoring decreases in very old age. Based on the results,
other patient groups seem to have equal access to health care
services regardless of their mental disorder. This finding is
consistent with earlier studies [25,27].
Previous studies have noted that keeping up with the rec-
ommended level of glucose is challenging because of the pro-
gressive nature of the disease, and gradual deterioration in b-
cell mass and function [36,37]. This might partly explain the
HbA1c decline among patient groups. For a better under-
standing of the results, we drew transition plots which
showed that during follow-up, a considerable number of
patients were shifting from very good HbA1c levels to moder-
ate levels, irrespective of the underlying mental disorder. This
further establishes the fact that maintenance of the recom-
mended glucose level is demanding when the disease is pro-
gressing. The population is also ageing and this affects the
treatment and its targets. Management of type 2 diabetes in
the elderly is more complicated because of the diversity in










P values HbA1c %, Mean (SD) P values
Baseline Follow-up Unadjusted Adjusted Baseline Follow-up Unadjusted Adjusted
Only type 2
diabetes
5016 68 (10.3) 46 75 (73–76) 66 (65–67) 6.58 (1.13) 6.88 (1.22)
Dementia 169 79 (6.6) 62 64 (56–71) 53 (45–61) < 0.001 < 0.001 6.85 (1.21) 7.09 (1.29) < 0.001 0.006
Depression 460 61 (11.7) 62 71 (67–75) 60 (55–65) 0.024 0.013 6.69 (1.35) 7.00 (1.37) 0.202 0.115
Other mental
disorder









P values LDL mmol/l, Mean (SD) P values
Baseline Follow up Unadjusted Adjusted Baseline Follow up Unadjusted Adjusted
Only type 2 diabetes 4746 67 (10.5) 45 55 (53–56) 62 (61–64) 2.48 (0.81) 2.36 (0.85)
Dementia 93 78 (7.1) 54 66 (55–75) 67 (56–76) 0.058 0.667 2.28 (0.70) 2.18 (0.86) 0.003 0.200
Depression 424 61 (11.1) 59 49 (44–54) 57 (52–61) 0.005 0.837 2.61 (0.87) 2.48 (0.99) 0.007 0.955
Other mental disorder 415 60 (11.2) 54 53 (48–58) 62 (58–67) 0.661 0.037 2.53 (0.86) 2.41 (0.86) 0.417 0.086
*Patients whose HbA1c was measured both at baseline and follow-up (n = 6070).
**Patients whose LDL was measured both baselines and follow-up (n = 5664).
Unadjusted and adjusted (age and gender) P values from the logistic and linear regression models with GEE for the changes in the achievement of HbA1c and LDL target and changes in the logarithmic
transformation of mean HbA1C values and mean LDL values of the patients with dementia, depression and other mental disorder compared with patients having only type 2 diabetes from baseline















































Fig. 1 – Transition of HbA1c levels of type 2 diabetes patient with andwithout mental disorders at six-year follow-up. (A) Type
2 diabetes patients with no mental disorders (N = 4763, se = 0.3–0.7%), (B) Type 2 diabetes patients with dementia (N = 161;
se = 2.0–3.9%), (C) Type 2 diabetes patients with depression (N = 443, se = 1.2–2.3%) and (D) Type 2 diabetes patients with other
mental disorder (N = 437, se = 1.1–2.3%).
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results emphasise the importance of incorporating individu-
ally tailored treatment into routine practice for the manage-
ment of type 2 diabetes.
This study showed differences in the changes of achieve-
ment of the target HbA1c level during follow-up among
patients with dementia and depression when compared with
those with only type 2 diabetes. Patients with dementia were
less likely to achieve the treatment target. Dementia patients
are usually older and the primary goals of diabetes manage-
ment for them include improving quality of life and self-
support rather than strict glycaemic control. According to
the guidelines, the HbA1c target for elderly patients could
be flexible (7.5–8.5% or 58–69 mmol/mol) based on chances
of hypoglycaemia and the presence of other complications
[33]. Therefore, it is not unexpected to see a difference in
HbA1c management in the dementia patient group compared
with those having only type 2 diabetes. It is most likely that
more individualised targets of glycaemic control have been
used for these patients to avoid hypoglycaemia. Another pos-
sible reason for the poor achievement of the treatment target
among dementia patients could be the non-adherence to the
medication. Several studies have identified a relationship
between cognitive impairment and poor adherence to the
medication. Forgetfulness, insufficient working memory and
executive functions in person with cognitive impairment
were found to be the reason for poor adherence to the medi-
cation [39–41].Furthermore, we noticed variations in glucose manage-
ment among depressive patients compared with those having
with only type 2 diabetes in our study, which is in agreement
with the earlier findings by Frayne et al. and Lustman et al.
[8,24]. A possible explanation for this might be that depressive
patients have reduced motivation for self-care and reduced
commitment to the treatment, leading to poorer treatment
outcomes [10,11]. In addition, patients with severe mental ill-
ness are often found to have poor quality of diabetes care [3]
due to the effect of their medication, which causes weight
gain and alters insulin sensitivity and secretion [42]. However,
we did not find any difference in the achievement of HbA1c
targets during the follow-up among patients from other men-
tal disorder groups compared with those having only type 2
diabetes. One reason for our finding may be the heterogeneity
of diagnoses included in the other mental disorders group, as
the number of those only having a severe mental illness in
our study population was too small to be analysed alone.
Another finding was that during the follow-up, an
enormous number of patients with poor LDL level were pro-
gressing towards moderate levels and the pattern was similar
for all patient groups. According to the guidelines, more
attention has recently been paid to the prevention of
macrovascular complications. The network of health profes-
sionals in North Karelia has also actively developed regional
practices in the care of type 2 diabetes patients.
The major strength of this study is that it included a
cohort of all diagnosed type 2 diabetes patients living in North
Fig. 2 – Transition of LDL levels of type 2 diabetes patient with and without mental disorders at six-year follow-up. (A) Type
2 diabetes patients with no mental disorders (N = 4437, se = 0.6–0.7%), (B) Type 2 diabetes patients with dementia (N = 73;
se = 5.1–5.8%), (C) Type 2 diabetes patients with depression (N = 397, se = 1.8–2.5%) and (D) Type 2 diabetes patients with
other mental disorder (N = 393, se = 1.9–2.5%).
d i a b e t e s r e s e a r c h a n d c l i n i c a l p r a c t i c e 1 6 6 ( 2 0 2 0 ) 1 0 8 3 1 2 7Karelia region and provided a six-year long follow-up includ-
ing information from both primary and secondary level care.
Data were collated directly from EHRs of the region and there-
fore selection bias, non-responsiveness of the patients and
missing laboratory data were avoided. Use of the same regio-
nal laboratory and standardized methods for HbA1c and LDL
measurements ensured the comparability of laboratory data
and the results between patients in different municipalities.
However, we also have some limitations in our study. Even
though most of the patients are treated on public sector there
are some who used only private health care services or who
did not use the service at all during the follow-up period. This
might cause some over or under estimation of achievement of
treatment targets. The other limitation is that as the quality
of manually entered information in EHRs is not yet optimal,
we were not able to use for example information on blood
pressure levels.
5. Conclusion
This study highlights the challenge of glucose level manage-
ment as the age and comorbidities of the patients influence
the care and achievements of the treatment targets. The exis-
tence of comorbidities such as mental disorders that are often
associated for example with patients’ adherence to medica-
tion and other treatments should be taken into account and
more support for self-care should be provided to suchpatients. The treatment of LDL seems to improve all the time
following the current guidelines bringing most likely benefits
to the prevention of macrovascular complications.Author contributions
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